Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.
2.

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.

Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E.

Vaccine. 2009 Aug 27;27(39):5393-401. doi: 10.1016/j.vaccine.2009.06.081. Epub 2009 Jul 9.

PMID:
19596415
3.
4.

Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes.

Tan L, Lu H, Zhang D, Tian M, Hu B, Wang Z, Jin N.

Virol J. 2010 Dec 7;7:363. doi: 10.1186/1743-422X-7-363.

5.

Epitope specific T-cell responses against influenza A in a healthy population.

Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S.

Immunology. 2016 Feb;147(2):165-77. doi: 10.1111/imm.12548. Epub 2015 Dec 8.

6.

Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.

Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2013 Jul;9(7):1598-607. doi: 10.4161/hv.25598. Epub 2013 Jul 11.

PMID:
23846304
7.

T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.

Rojas JM, Rodríguez-Calvo T, Peña L, Sevilla N.

Vaccine. 2011 Sep 16;29(40):6848-57. doi: 10.1016/j.vaccine.2011.07.061. Epub 2011 Jul 30.

PMID:
21807057
8.

Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase.

Gupta SK, Srivastava M, Akhoon BA, Smita S, Schmitz U, Wolkenhauer O, Vera J, Gupta SK.

Infect Genet Evol. 2011 Mar;11(2):308-19. doi: 10.1016/j.meegid.2010.10.013. Epub 2010 Nov 19.

PMID:
21094280
9.

Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage.

He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C.

BMC Bioinformatics. 2014;15 Suppl 4:S1. doi: 10.1186/1471-2105-15-S4-S1. Epub 2014 Mar 19.

14.

A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.

Oyarzun P, Ellis JJ, Gonzalez-Galarza FF, Jones AR, Middleton D, Boden M, Kobe B.

Vaccine. 2015 Mar 3;33(10):1267-73. doi: 10.1016/j.vaccine.2015.01.040. Epub 2015 Jan 25.

PMID:
25629524
15.
16.

The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination.

Kovalik JP, Singh N, Mendiratta SK, Martin WD, Ignatowicz L, Van Kaer L.

J Immunol. 2000 Aug 1;165(3):1285-93.

17.

In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.

Gutiérrez AH, Loving C, Moise L, Terry FE, Brockmeier SL, Hughes HR, Martin WD, De Groot AS.

PLoS One. 2016 Jul 13;11(7):e0159237. doi: 10.1371/journal.pone.0159237. eCollection 2016.

18.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
19.

Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies.

Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B.

J Immunol. 2002 Mar 1;168(5):2154-62.

20.

Supplemental Content

Support Center